Working Together on a New Future in Cancer Therapy
TILT Biotherapeutics is the world’s leading company developing investigational oncolytic immunotherapies to enable T-cell therapy of solid tumors.
We collaborate with industry-leading pharmaceutical companies to enhance the therapeutic efficacy of in-development cancer immunotherapies by stimulating T cells with our TILT® technology.
Company’s current partnerships include:
- Merck & Co., Inc. (US) for pembrolizumab (KEYTRUDA®) in ovarian and lung cancer studies.
- Merck KGgA (Germany) for avelumab (BAVENCIO®) in combination with TILT-123 for melanoma and, head and neck cancer studies.
As part of TILT Biotherapeutics’ partnership strategies, clinical collaborations are critical for generating data on combination therapies. In addition, company’s patented technology will be available for licensing to support the commercialization of its pipeline.
TILT® technology can be a valuable asset for the immune-oncology pipeline of big pharmaceutical companies.